These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6779018)

  • 1. Implications for health care policy. A social and demographic profile of hemodialysis patients in the United States.
    Evans RW; Blagg CR; Bryan FA
    JAMA; 1981 Feb; 245(5):487-91. PubMed ID: 6779018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the medicare ESRD program pay for daily dialysis? An ethical analysis.
    Anantharaman P; Moss AH
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):290-6. PubMed ID: 17603984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval.
    Powe NR; Griffiths RI; de Lissovoy G; Anderson GF; Watson AJ; Greer JW; Herbert RJ; Eggers PW; Milam RA; Whelton PK
    JAMA; 1992 Sep; 268(11):1434-40. PubMed ID: 1512912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited resources and the treatment of end-stage renal failure in Britain and the United States.
    Rennie D; Rettig RA; Wing AJ
    Q J Med; 1985 Jul; 56(219):321-36. PubMed ID: 3912791
    [No Abstract]   [Full Text] [Related]  

  • 5. Medicare Program; End-Stage Renal Disease Prospective Payment System, Coverage and Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program Bid Surety Bonds, State Licensure and Appeals Process for Breach of Contract Actions, Durable Medical Equipment, Prosthetics, Orthotics and Supplies Competitive Bidding Program and Fee Schedule Adjustments, Access to Care Issues for Durable Medical Equipment; and the Comprehensive End-Stage Renal Disease Care Model. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2016 Nov; 81(214):77834-969. PubMed ID: 27905888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of care for patients with chronic kidney disease in the United States: dying for improvement.
    Owen WF
    J Am Soc Nephrol; 2003 Jul; 14(7 Suppl 2):S76-80. PubMed ID: 12819307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access.
    Lee H; Manns B; Taub K; Ghali WA; Dean S; Johnson D; Donaldson C
    Am J Kidney Dis; 2002 Sep; 40(3):611-22. PubMed ID: 12200814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationing of health care and the end-stage renal disease program.
    Klahr S
    Am J Kidney Dis; 1990 Oct; 16(4):392-5. PubMed ID: 2220792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidneys, ethics, and politics: policy lessons of the ESRD experience.
    Caplan AL
    J Health Polit Policy Law; 1981; 6(3):488-503. PubMed ID: 7033349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESRD managed care demonstration: financial implications.
    Dykstra DM; Beronja N; Menges J; Gaylin DS; Oppenheimer CC; Shapiro JR; Wolfe RA; Rubin RJ; Held PJ
    Health Care Financ Rev; 2003; 24(4):59-75. PubMed ID: 14628400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dialysis and transplant.
    Waterfall WK
    Br Med J; 1980 Sep; 281(6242):726-7. PubMed ID: 7000276
    [No Abstract]   [Full Text] [Related]  

  • 14. The success of medicare's end-stage renal-disease program: the case for profits and the private marketplace.
    Lowrie EG; Hampers CL
    N Engl J Med; 1981 Aug; 305(8):434-8. PubMed ID: 7019710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The organization of medical care. Lessons from the Medicare end stage renal disease program.
    Levinsky NG
    N Engl J Med; 1993 Nov; 329(19):1395-9. PubMed ID: 8413437
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis.
    Mehrotra R; Marsh D; Vonesh E; Peters V; Nissenson A
    Kidney Int; 2005 Jul; 68(1):378-90. PubMed ID: 15954930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health policy report. Funding the End-Stage Renal-Disease Program.
    Iglehart JK
    N Engl J Med; 1982 Feb; 306(8):492-6. PubMed ID: 7035954
    [No Abstract]   [Full Text] [Related]  

  • 18. Epidemiology of end stage renal disease and implications for public policy.
    Rubin RJ
    Public Health Rep; 1984; 99(5):492-8. PubMed ID: 6435162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medicare program; end-stage renal disease quality incentive program. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2011 Jan; 76(3):627-46. PubMed ID: 21261127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The financial implications for Medicare of greater use of peritoneal dialysis.
    Neil N; Guest S; Wong L; Inglese G; Bhattacharyya SK; Gehr T; Walker DR; Golper T
    Clin Ther; 2009 Apr; 31(4):880-8. PubMed ID: 19446160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.